Merck & Co has stopped a late-stage clinical trial of its anti-clotting drug, vorapaxar, and restricted a second study on the advice of an independent data and safety monitoring board. A regulatory filing for the drug had been planned in 2011. ---Subscribe to MedNous to access this article--- Company News
